Advances in Economics, Management and Political Sciences
- The Open Access Proceedings Series for Conferences
Proceedings of the 2023 International Conference on Management Research and Economic Development
Series Vol. 25 , 13 September 2023
Open
Access | Article
Pfizer Inc.'s Financial Performance: An Evaluation of Growth and Profitability
* Author to whom correspondence should be addressed.
Abstract
Based on Pfizer's 2021 annual report, this paper explored whether Pfizer's ac-counting policy is accurate, whether the company's strategic adjustments for the future are achievable, and whether Pfizer's performance is good in com-parison with its industry peers. By analyzing Pfizer's accounting standards, this analysis concluded that Pfizer's accounting policy is relatively accurate. Pfizer adopted a new accounting standard for income taxes that eliminates certain exceptions related to the method of allocating tax for the period. To analyze whether Pfizer's strategic adjustment for the company's future de-velopment is achievable, this paper has analyzed the situation of the general environment in 2022 and 2023 and the characteristics of Pfizer's industry, from which this paper concluded that Pfizer's strategic adjustment is a clear choice, although it requires time and effort. It is worth noting that Pfizer made a significant acquisition in 2021. When comparing Pfizer with its competitors, this paper chose to compare the performance, leverage, and li-quidity of Pfizer with its competitors, each of which contains two to three key ratios, and by comparing these data, this analysis concluded that Pfizer is still outstanding when compared with its competitors, and it is a company that investors can trust.
Keywords
fundamental analysis, performance evaluation, investment potential, pharmaceutical industry
References
1. Nolen, J. L. Pfizer, Inc.. Encyclopedia Britannica. https://www.britannica.com/topic/Pfizer-Inc, last accessed 2023/3/20.
2. Pfizer Completes Acquisition of Arena Pharmaceuticals. Pfizer.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals, last accessed 2023/3/20.
3. Pfizer’s Arena goal? Get out of the way and don’t “break the new toy.” Fierce Biotech. https://www.fiercebiotech.com/biotech/pfizers-arena-goal-get-out-way-and-dont-break-new-toy, last accessed 2023/3/20.
4. Pfizer 2021 annual report.https://s28.q4cdn.com/781576035/files/doc_financials/2021/ar/PFE-2021-Form-10K-FINAL, last accessed 2023/3/20.
5. AbbVie 2021 annual report.https://investors.abbvie.com/static-files/91cf9d6a-8e6f-4059-9575-eda83b7e4623, last accessed 2023/3/20.
6. Merck 2021 annual report.https://s21.q4cdn.com/488056881/files/doc_financials/2021/q4/Form-10-K-2021-Final, last accessed 2023/3/20.
7. Eli Lilly 2021 annual report. https://investor.lilly.com/static-files/6ae2e79a-1256-4e4d-b646-a40fca701519, last accessed 2023/3/20.
8. Johnson & Johnson 2021 annual report. https://www.investor.jnj.com/annual-meeting-materials/2021-annual-report, last accessed 2023/3/20.
9. Healthcare Services Current Ratio 2010-2022. HCSG. MacroTrends. https://www.macrotrends.net/stocks/charts/HCSG/healthcare-services/current-ratio, last accessed 2023/3/20.
10. Kimball, S. The Covid pandemic drives Pfizer’s 2022 revenue to a record $100 billion. CNBC. https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html, last accessed 2023/3/20.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2023 International Conference on Management Research and Economic Development
- ISBN (Print)
- 978-1-915371-93-5
- ISBN (Online)
- 978-1-915371-94-2
- Published Date
- 13 September 2023
- Series
- Advances in Economics, Management and Political Sciences
- ISSN (Print)
- 2754-1169
- ISSN (Online)
- 2754-1177
- DOI
- 10.54254/2754-1169/25/20230480
- Copyright
- 13 September 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited